RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies today announced that it will present new data demonstrating the influence of tunable PRINT® (Particle Replication In Non-Wetting Templates) particle characteristics on the immune response as a component of vaccine development. Results from this preclinical study will be presented at the 9th Annual ImVacS, The Immunotherapies and Vaccine Summit, being held August 11-14, 2014 in Boston, Massachusetts. The ImVacS Summit brings together a global audience of vaccine researchers and developers of cancer immunotherapies for five focused meetings that explore the frontiers of immunology as the basis for patient treatment.
Michele Stone, Ph.D., PMP, Liquidia’s Director, Vaccines will give an oral presentation titled Exploring the Role of Size and Shape Impact on Immune Response through PRINT Technology in a special session, Vaccine Delivery Innovations, being held today at 3:45PM in Salon ABCG at the Marriott Long Wharf Hotel.
The PRINT technology is an innovative, highly tunable and scalable particle engineering process that allows Liquidia researchers to precisely tailor particle size, shape, charge, hydrophobicity, and composition of vaccines with the goal of optimizing a vaccine’s ability to elicit the desired immune response. By using a broad range of matrix materials formulated with active antigens and adjuvants, Liquidia has leveraged the PRINT technology to define particles of specific sizes and shapes that appear to have superior effects on humoral and cellular immune responses.
Vaccines are a front line defense against many, often life threatening diseases. Liquidia’s PRINT technology is aimed at finding innovative solutions that can address many of the challenges often encountered in vaccine development with the ultimate goal of creating safe and efficacious vaccines that can provide the broadest possible protection for a global population.
ABOUT LIQUIDIA TECHNOLOGIES
Liquidia Technologies, founded in 2004, is a privately held biotechnology company located in Research Triangle Park, North Carolina. By leveraging precise fabrication techniques of the semiconductor industry, Liquidia has become the only company in the world with the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition using a unique particle engineering and manufacturing process known as the PRINT® (Particle Replication In Non-Wetting Templates) technology. This unique ability to precisely engineer particles enables scientists to explore new product frontiers that, until now, have been out of reach for the life sciences industry. Liquidia is currently exploring the application of this novel technology to develop products in several high growth areas such as vaccines and pulmonology. In addition, Liquidia licenses the PRINT particle technology and its cGMP manufacturing capabilities to support proprietary programs advanced by collaborators. For more information, please go to www.liquidia.com.
ABOUT THE PRINT® TECHNOLOGY
By leveraging precise fabrication techniques of the semiconductor industry, the PRINT® (Particle Replication In Non-Wetting Templates) technology is the only platform in the world with the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape or chemistry, including small molecule active pharmaceutical ingredients (API), biologic APIs, and polymeric drug delivery systems (e.g. extended release formulations). This unique ability to precisely engineer micro- and nanoparticles enables scientists to explore new product frontiers that, until now, have otherwise been out of reach for the life sciences industry.